

GEHONOREERDE PROJECTEN ALPE D'HUZES-THEMA DIAGNOSTIEK, BEHANDELING & REGISTRATIE



| Projectnummer | Titel | Projectleider | Instituut | Kankersoort | Goedgekeurd budget |
|---------------|---|-----------------------|--|---|--------------------|
| 5842 | The Dutch Pancreatic Cancer Project (PACAP): prospective multicenter registry, biobank, online expertpanel and intervention study | Marc Besselink | Amsterdam UMC | Alvleesklier | € 1.402.450,00 |
| 6331 | Improving clinical management of colon cancer through CONNECTION, a nation-wide Colon Cancer Registry and Stratification effort. | Jan Paul Medema | Amsterdam UMC | Dikkedarm | € 3.367.235,00 |
| 6269 | Development of a HOVON Lymphoma Biobank Facility | Daphne de Jong | Amsterdam UMC (locatie VUmc) | Non-hodgkinlymfoom | € 1.197.015,00 |
| 6371 | Identification of under-treated and over-treated acute myeloid leukemia patients, using minimal residual disease and leukemia stem cell frequency | Gerrit Schuurhuis | Amsterdam UMC (locatie VUmc) | Leukemie | € 409.120,00 |
| 6249 | Safety, feasibility and cost-effectiveness of genotype- and phenotype-directed individualized dosing of fluoropyrimidines | Annemieke Cats | Antoni van Leeuwenhoek / Nederlands Kanker Instituut | Algemeen (niet-kankersoortspecifiek) | € 1.146.640,00 |
| 6250 | MANAGEMENT OF LOW RISK DUCTAL CARCINOMA IN SITU: WATCHFUL WAITING OR NOT? A RANDOMIZED, NON-INFERIORITY TRIAL | Jelle Wesseling | Antoni van Leeuwenhoek / Nederlands Kanker Instituut | Borst | € 740.920,00 |
| 6253 | Risk management of contralateral breast cancer: development and validation of an online decision aid for physicians and patients. | Marjanka Schmidt | Antoni van Leeuwenhoek / Nederlands Kanker Instituut | Borst | € 1.193.720,00 |
| 6338 | Molecular stool test for postpolypectomy surveillance | Gerrit Meijer | Antoni van Leeuwenhoek / Nederlands Kanker Instituut | Dikkedarm | € 1.498.900,00 |
| 6340 | Determination of new biological parameters in patients with resectable colorectal liver metastases | Kees Verhoef | Erasmus MC Rotterdam | Dikkedarm | € 1.314.194,00 |
| 6286 | Optimizing palliative treatment in patients with bone metastases of the long bones: the OPTIMAL study | Sander Dijkstra | LUMC Leiden | Bot | € 509.855,00 |
| 6311 | Brachytherapy for rectal cancer: a better balance between tumor control and side effects | Corrie Marijnen | LUMC Leiden | Dikkedarm | € 1.357.200,00 |
| 6229 | Gadofosveset-enhanced axillary MRI for re-staging of axillary lymph nodes after neoadjuvant systemic therapy in clinical node positive breast cancer patients | Marc Lobbes | Maastricht UMC+ (Maastricht University) | Borst | € 496.980,00 |
| 6374 | Decision-support for couples with hereditary cancer and child wish: weighing pros and cons of reproductive options regarding transmission of gene mutations | Liesbeth van Osch | Maastricht UMC+ (Maastricht University) | Algemeen (niet-kankersoortspecifiek) | € 453.163,00 |
| 6251 | ELDAPT: Elderly with locally advanced Lung cancer: Deciding through geriatric Assessment on the oPtimal Treatment strategy | Anne-Marie Dingemans | MAASTRO clinic | Long | € 1.298.500,00 |
| 6281 | A randomized trial comparing conventional with stereotactic radiotherapy for pain reduction and quality of life in spinal metastases | Petra Braam | Radboudumc | Bot | € 1.075.230,00 |
| 6354 | Towards an optimal diagnosis: standardization of pathology reporting | Iris Nagtegaal | Radboudumc | Borst; Dikkedarm | € 153.900,00 |
| 6267 | INFLAME: towards optimal treatment of inflammatory breast cancer patients | Carolien Schröder | UMC Groningen | Borst | € 530.960,00 |
| 6345 | Towards evidence based guidelines for supportive care in childhood oncology | Wim Tissing | UMC Groningen | Hersenen; Leukemie; Neuroblastoom; Nier; Non-hodgkinlymfoom; Sarcoom (wekedelentumor); Zenuwstelsel | € 391.800,00 |
| 6355 | Treatment of gastrointestinal stromal tumors based on serial mutation analysis of circulating tumor DNA: GALLOP. | An Reyners | UMC Groningen | Dikkedarm; GIST; Maag; Slokdarm | € 1.446.155,00 |
| 6302 | Saving breast cancer patients from ineffective cytotoxic treatment | Maurice van den Bosch | UMC Utrecht | Borst | € 981.340,00 |

Totaal € 20.965.277,00